Edmond DE Rothschild Holding S.A. Purchases Shares of 13,500 Natera, Inc. $NTRA

Edmond DE Rothschild Holding S.A. acquired a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, Holdings Channel reports. The firm acquired 13,500 shares of the medical research company’s stock, valued at approximately $3,665,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Trust Co. of Vermont acquired a new stake in Natera in the second quarter valued at approximately $26,000. Reflection Asset Management purchased a new position in Natera in the fourth quarter worth approximately $29,000. Elevation Wealth Partners LLC acquired a new position in Natera during the 2nd quarter worth approximately $30,000. Palladiem LLC acquired a new position in Natera during the 4th quarter worth approximately $31,000. Finally, Horizon Investments LLC purchased a new stake in shares of Natera in the 3rd quarter valued at approximately $32,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of analyst reports. Piper Sandler raised their price objective on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Guggenheim increased their target price on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $319.38.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the transaction, the insider owned 183,774 shares of the company’s stock, valued at $49,249,594.26. This represents a 0.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 over the last quarter. 5.05% of the stock is owned by insiders.

Natera Trading Up 4.3%

NTRA stock opened at $325.07 on Thursday. The stock has a market cap of $46.86 billion, a P/E ratio of -239.02 and a beta of 1.51. Natera, Inc. has a twelve month low of $156.71 and a twelve month high of $326.03. The company’s 50 day moving average is $269.73 and its two-hundred day moving average is $228.01.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.74) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.